Literature DB >> 21723297

Cross-bridge kinetics in myofibrils containing familial hypertrophic cardiomyopathy R58Q mutation in the regulatory light chain of myosin.

P Mettikolla1, N Calander, R Luchowski, I Gryczynski, Z Gryczynski, J Zhao, D Szczesna-Cordary, J Borejdo.   

Abstract

Familial hypertrophic cardiomyopathy (FHC) is a heritable form of cardiac hypertrophy caused by single-point mutations in genes encoding sarcomeric proteins including ventricular myosin regulatory light chain (RLC). FHC often leads to malignant outcomes and sudden cardiac death. The FHC mutations are believed to alter the kinetics of the interaction between actin and myosin resulting in inefficient energy utilization and compromised function of the heart. We studied the effect of the FHC-linked R58Q-RLC mutation on the kinetics of transgenic (Tg)-R58Q cardiac myofibrils. Kinetics was determined from the rate of change of orientation of actin monomers during muscle contraction. Actin monomers change orientation because myosin cross-bridges deliver periodic force impulses to it. An individual impulse (but not time average of impulses) carries the information about the kinetics of actomyosin interaction. To observe individual impulses it was necessary to scale down the experiments to the level of a few molecules. A small population (∼4 molecules) was selected by using (deliberately) inefficient fluorescence labeling and observing fluorescent molecules by a confocal microscope. We show that the kinetic rates are significantly smaller in the contracting cardiac myofibrils from Tg-R58Q mice then in control Tg-wild type (WT). We also demonstrate a lower force per cross-section of muscle fiber in Tg-R58Q versus Tg-WT mice. We conclude that the R58Q mutation-induced decrease in cross-bridge kinetics underlines the mechanism by which Tg-R58Q fibers develop low force and thus compromise the ability of the mutated heart to efficiently pump blood.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723297      PMCID: PMC3152379          DOI: 10.1016/j.jtbi.2011.06.014

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  55 in total

1.  Effects of sarcomere length and temperature on the rate of ATP utilisation by rabbit psoas muscle fibres.

Authors:  K Hilber; Y B Sun; M Irving
Journal:  J Physiol       Date:  2001-03-15       Impact factor: 5.182

Review 2.  The young competitive athlete with cardiovascular abnormalities: causes of sudden death, detection by preparticipation screening, and standards for disqualification.

Authors:  Barry J Maron
Journal:  Card Electrophysiol Rev       Date:  2002-02

3.  Three myosin V structures delineate essential features of chemo-mechanical transduction.

Authors:  Pierre-Damien Coureux; H Lee Sweeney; Anne Houdusse
Journal:  EMBO J       Date:  2004-10-28       Impact factor: 11.598

4.  Individual states in the cycle of muscle contraction.

Authors:  C G Dos Remedios; R G Yount; M F Morales
Journal:  Proc Natl Acad Sci U S A       Date:  1972-09       Impact factor: 11.205

5.  Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle.

Authors:  K Poetter; H Jiang; S Hassanzadeh; S R Master; A Chang; M C Dalakas; I Rayment; J R Sellers; L Fananapazir; N D Epstein
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

6.  Polarized fluorescence correlation spectroscopy of DNA-DAPI complexes.

Authors:  Maria Luisa Barcellona; Seth Gammon; Theodore Hazlett; Michelle A Digman; Enrico Gratton
Journal:  Microsc Res Tech       Date:  2004-11       Impact factor: 2.769

7.  Myosin light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology.

Authors:  Timothy M Olson; Margaret L Karst; Frank G Whitby; David J Driscoll
Journal:  Circulation       Date:  2002-05-21       Impact factor: 29.690

8.  One third of Danish hypertrophic cardiomyopathy patients with MYH7 mutations have mutations [corrected] in MYH7 rod region.

Authors:  Lotte Hougs; Ole Havndrup; Henning Bundgaard; Lars Køber; Jens Vuust; Lars Allan Larsen; Michael Christiansen; Paal Skytt Andersen
Journal:  Eur J Hum Genet       Date:  2005-02       Impact factor: 4.246

9.  Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden.

Authors:  Stellan Mörner; Pascale Richard; Elsadig Kazzam; Urban Hellman; Bernard Hainque; Ketty Schwartz; Anders Waldenström
Journal:  J Mol Cell Cardiol       Date:  2003-07       Impact factor: 5.000

10.  Studies on conformation of F-actin in muscle fibers in the relaxed state, rigor, and during contraction using fluorescent phalloidin.

Authors:  E Prochniewicz-Nakayama; T Yanagida; F Oosawa
Journal:  J Cell Biol       Date:  1983-12       Impact factor: 10.539

View more
  17 in total

1.  Phosphorylation of myosin regulatory light chain has minimal effect on kinetics and distribution of orientations of cross bridges of rabbit skeletal muscle.

Authors:  Divya Duggal; Janhavi Nagwekar; Ryan Rich; Krishna Midde; Rafal Fudala; Ignacy Gryczynski; Julian Borejdo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-11-27       Impact factor: 3.619

2.  Effect of a myosin regulatory light chain mutation K104E on actin-myosin interactions.

Authors:  D Duggal; J Nagwekar; R Rich; W Huang; K Midde; R Fudala; H Das; I Gryczynski; D Szczesna-Cordary; J Borejdo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-13       Impact factor: 4.733

Review 3.  Mesoscopic analysis of motion and conformation of cross-bridges.

Authors:  J Borejdo; R Rich; K Midde
Journal:  Biophys Rev       Date:  2012-04-17

4.  Comparison of orientation and rotational motion of skeletal muscle cross-bridges containing phosphorylated and dephosphorylated myosin regulatory light chain.

Authors:  Krishna Midde; Ryan Rich; Peter Marandos; Rafal Fudala; Amy Li; Ignacy Gryczynski; Julian Borejdo
Journal:  J Biol Chem       Date:  2013-01-14       Impact factor: 5.157

5.  Phosphorylation of cMyBP-C affects contractile mechanisms in a site-specific manner.

Authors:  Li Wang; Xiang Ji; David Barefield; Sakthivel Sadayappan; Masakata Kawai
Journal:  Biophys J       Date:  2014-03-04       Impact factor: 4.033

6.  Using baculovirus/insect cell expressed recombinant actin to study the molecular pathogenesis of HCM caused by actin mutation A331P.

Authors:  Fan Bai; Hannah M Caster; Peter A Rubenstein; John F Dawson; Masataka Kawai
Journal:  J Mol Cell Cardiol       Date:  2014-04-30       Impact factor: 5.000

7.  High ionic strength depresses muscle contractility by decreasing both force per cross-bridge and the number of strongly attached cross-bridges.

Authors:  Li Wang; Anzel Bahadir; Masataka Kawai
Journal:  J Muscle Res Cell Motil       Date:  2015-04-03       Impact factor: 2.698

8.  Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathy.

Authors:  Katarzyna Kazmierczak; Ellena C Paulino; Wenrui Huang; Priya Muthu; Jingsheng Liang; Chen-Ching Yuan; Ana I Rojas; Joshua M Hare; Danuta Szczesna-Cordary
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-06-07       Impact factor: 4.733

9.  Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with MYL2-R58Q-Mediated Apical Hypertrophic Cardiomyopathy Show Hypertrophy, Myofibrillar Disarray, and Calcium Perturbations.

Authors:  Wei Zhou; J Martijn Bos; Dan Ye; David J Tester; Sybil Hrstka; Joseph J Maleszewski; Steve R Ommen; Rick A Nishimura; Hartzell V Schaff; Chang Sung Kim; Michael J Ackerman
Journal:  J Cardiovasc Transl Res       Date:  2019-02-22       Impact factor: 4.132

10.  Diversity and similarity of motor function and cross-bridge kinetics in papillary muscles of transgenic mice carrying myosin regulatory light chain mutations D166V and R58Q.

Authors:  Li Wang; Priya Muthu; Danuta Szczesna-Cordary; Masataka Kawai
Journal:  J Mol Cell Cardiol       Date:  2013-05-29       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.